Ocular drug delivery: present innovations and future challenges

V Gote, S Sikder, J Sicotte, D Pal - Journal of Pharmacology and …, 2019 - ASPET
Ocular drug delivery has always been a challenge for ophthalmologists and drug-delivery
scientists due to the presence of various anatomic and physiologic barriers. Inimitable static …

Corticosteroids in ophthalmology: Drug delivery innovations, pharmacology, clinical applications, and future perspectives

SA Gaballa, UB Kompella, O Elgarhy… - Drug Delivery and …, 2021 - Springer
Corticosteroids remain the mainstay of the treatment for various ocular conditions affecting
the ocular surface, anterior and posterior segments of the eye due to their anti-inflammatory …

Advanced formulation approaches for ocular drug delivery: state-of-the-art and recent patents

EB Souto, J Dias-Ferreira, A López-Machado… - Pharmaceutics, 2019 - mdpi.com
The eye presents extensive perspectives and challenges for drug delivery, mainly because
of the extraordinary capacity, intrinsic to this path, for drugs to permeate into the main …

[HTML][HTML] A review on recent drug delivery systems for posterior segment of eye

K Nayak, M Misra - Biomedicine & pharmacotherapy, 2018 - Elsevier
Eye is the unique sense organ with complex and sophisticated anatomy and physiology.
Being most instrumental for vision, it is secured by varied protective barriers; ranging from …

Interim results from the international trial of Second Sight's visual prosthesis

MS Humayun, JD Dorn, L Da Cruz, G Dagnelie… - Ophthalmology, 2012 - Elsevier
PURPOSE: This study evaluated the Argus II Retinal Prosthesis System (Second Sight
Medical Products, Inc., Sylmar, CA) in blind subjects with severe outer retinal degeneration …

Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis

C Lowder, R Belfort, S Lightman… - Archives of …, 2011 - jamanetwork.com
Objective: To evaluate the safety and efficacy of 2 doses of dexamethasone intravitreal
implant (DEX implant) for treatment of noninfectious intermediate or posterior uveitis …

[HTML][HTML] Intravitreal hydrogels for sustained release of therapeutic proteins

BC Ilochonwu, A Urtti, WE Hennink… - Journal of Controlled …, 2020 - Elsevier
This review highlights how hydrogel formulations can improve intravitreal protein delivery to
the posterior segment of the eye in order to increase therapeutic outcome and patient …

Ocular delivery of proteins and peptides: Challenges and novel formulation approaches

A Mandal, D Pal, V Agrahari, HM Trinh… - Advanced drug delivery …, 2018 - Elsevier
The impact of proteins and peptides on the treatment of various conditions including ocular
diseases over the past few decades has been advanced by substantial breakthroughs in …

Ocular sarcoidosis

S Pasadhika, JT Rosenbaum - Clinics in chest medicine, 2015 - chestmed.theclinics.com
Ocular involvement of sarcoidosis has been known since the early 1900s and has become
more recognized since the mid-1900s. 1 Variability in the diagnostic criteria has made …

Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema

PA Campochiaro, DM Brown, A Pearson, T Ciulla… - Ophthalmology, 2011 - Elsevier
Objective To assess the efficacy and safety of intravitreal inserts releasing 0.2 μg/day (low
dose) or 0.5 μg/day (high dose) fluocinolone acetonide (FA) in patients with diabetic macular …